• Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials
healthcare providers

William Owen, MD

Healthcare provider
Pediatric Hematologist-Oncologist
Children's Hospital of The King's Daughters
601 Children's Lane
Norfolk, Virginia, United States

Dr. William Owen is a pediatric hematology/oncology specialist at the Children’s Hospital of The King’s Daughters. His clinical interest includes treating patients with leukemia, sickle cell disease, immunological diseases which affect the blood and bone marrow and histiocytic diseases. Dr. William has served as the leader in the development of several clinical programs at the hospital, including the peripheral stem cell transplantation and comprehensive sickle cell programs. 

Dr. Owen has also served in various roles on regional, state and national committees ranging from chairman of the EVMS admissions committee to a participant on the sickle cell disease expert panel for development of quality of care indicators at Boston University.

Dr. William Owen has a strong interest in global health and has made multiple trips to Haiti and the Dominican Republic to provide direct health care, to help establish medical screening programs, and to aid in the educational process of local medical providers.


Representative Publications:

Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial

Increased prevalence of potential right-to-left shunting in children with sickle cell anaemia and stroke

Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial

Effects of chronic transfusions on abdominal sonographic abnormalities in children with sickle cell anemia

Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: A report from the multi-center study of iron overload


expertly curated content related to this topic

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.